High-dose peripheral blood stem cell transplant for multitransfused severe aplastic anaemia patients without antithymocyte globulin in the conditioning regimen

被引:21
作者
Herrera-Garza, JL
Jaime-Pérez, JC
Montemayor, JL
Ibarra-Peart, RE
Gómez-Almaguer, D
机构
[1] Dr Jose E Gonzalez Univ Hosp, Dept Haematol, Monterrey, Mexico
[2] Autonomous Univ Nuevo Leon, Sch Med, Monterrey, Mexico
关键词
severe aplastic anaemia; bone marrow transplant; antithymocyte globulin; peripheral blood stem cell; transplant; graft failure;
D O I
10.1038/sj.bmt.1701986
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Pour multitransfused patients with severe aplastic anaemia (SAA) are described. Two received a BMT after conditioning with cyclophosphamide (Cy) plus antithymocyte globulin (ATG), Both suffered a graft failure (GF) and had a second transplant with PBSC from the original donor. Two other patients received a PBSCT as a first option, with Cy as the only conditioning drug, The four patients received methotrexate (MTX) and cyclosporine (CYA) as post-grafting immunosuppression. The two BMT patients with GF were successfully rescued with a PBSC second transplant, In the two cases where a PBSCT was done as a first option no GF was observed and a successful and complete haematological recovery was achieved, In conclusion, PBSCT rescued two SAA patients with GF after BMT, PBSCT without ATG as a first option produced a quick and complete haematological recovery in two additional patients, suggesting that PBSCT without ATG can be an alternative to BMT plus ATG in SAA as a first transplant option.
引用
收藏
页码:845 / 848
页数:4
相关论文
共 19 条
[1]  
ARENDS T, 1992, ENCICLOPEDIA IBEROAM
[2]  
BOLGER GB, 1986, BONE MARROW TRANSPL, V1, P21
[3]  
DELGADOLAMAS LJ, 1989, ACTA HAEMATOL, V81, P70
[4]   Primary transplantation of allogeneic peripheral blood stem cell for severe aplastic anemia [J].
Hsu, HC ;
Tsai, WH ;
Lin, JS ;
Tzeng, CH ;
Wang, SY ;
Ho, CH .
ANNALS OF HEMATOLOGY, 1997, 74 (04) :191-192
[5]   ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION FOR REFRACTORY LEUKEMIA AND LYMPHOMA - POTENTIAL ADVANTAGE OF BLOOD OVER MARROW ALLOGRAFTS [J].
KORBLING, M ;
PRZEPIORKA, D ;
HUH, YO ;
ENGEL, H ;
VANBESIEN, K ;
GIRALT, S ;
ANDERSSON, B ;
KLEINE, HD ;
SEONG, D ;
DEISSEROTH, AB ;
ANDREEFF, M ;
CHAMPLIN, R .
BLOOD, 1995, 85 (06) :1659-1665
[6]  
Majolino I, 1996, BONE MARROW TRANSPL, V17, P555
[7]   Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection [J].
Martin, PJ ;
Akatsuka, Y ;
Hahne, M ;
Sale, G .
BLOOD, 1998, 92 (06) :2177-2181
[8]  
NIDERWIESER D, 1988, BRIT J HAEMATOL, V69, P23
[9]   Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation [J].
Pérez-Simón, JA ;
Caballero, MD ;
Corral, M ;
Nieto, MJ ;
Orfao, A ;
Vazquez, L ;
Amigo, ML ;
Berges, C ;
González, M ;
Del Cañizo, C ;
San Miguel, JF .
TRANSFUSION, 1998, 38 (04) :385-391
[10]   Successful engraftment after primary graft failure in aplastic anemia using G-CSF mobilized peripheral stem cell transfusions [J].
Redei, I ;
Waller, EK ;
Holland, HK ;
Devine, SM ;
Wingard, JR .
BONE MARROW TRANSPLANTATION, 1997, 19 (02) :175-177